The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BackgroundIMC‐A12, a fully human antibody that blocks ligand binding to the Type 1 insulin‐like growth factor receptor, and rapamycin, a selective inhibitor of mTORC1 signaling, have both demonstrated significant antitumor activity against PPTP solid tumor models. Here we have evaluated antitumor activity of each agent individually and in combination against nine tumor models.
ProceduresIMC‐A12 was...
BackgroundMany childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type‐1‐insulin‐like growth factor receptor (IGF‐1R), and the autocrine production of its ligands IGF‐1/IGF‐2. IMC‐A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF‐1R.
ProceduresIMC‐A12 was evaluated against the 23 cell lines of the Pediatric Preclinical...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.